Shares of Resmed (ASX:RMD) fell 2% on recent Tuesday trade after it received US Food and Drug Administration clearance for a medical device that provides personalized comfort settings to help people with obstructive sleep apnea stay on Continuous Positive Airway Pressure (CPAP) therapy, according to a Monday statement.
The device will launch in early 2026, the statement said.